clofazimine (lamprene) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Clofazimine (Lamprene®) is a fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine (Lamprene®) exerts a slow bactericidal effect on Mycobacterium leprae (Hansen’s bacillus). It inhibits mycobacterial growth and binds preferentially to mycobacterial DNA. It also exerts anti-inflammatory properties in controlling erythema nodosum leprosum reactions. However, its precise mechanisms of action are unknown.   NCATS

Chemistry

  • SMILES: CC(C)\N=C1/C=C2N(C3=CC=C(Cl)C=C3)C4=C(C=CC=C4)N=C2C=C1NC5=CC=C(Cl)C=C5
  • InChIKey: WDQPAMHFFCXSNU-BGABXYSRSA-N
  • Mol. Mass: 473.396
  • ALogP: 7.49
  • ChEMBL Molecule:
    clofazimine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

chlofazimine | clofazimin | clofazimina | clofazimine | clofaziminum | g-30320 | lamprene | riminophenazine

Organizations (94)

Research & Development (94)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (18)

Approved Indications (1)


 

Leprosy, Lepromatous (approved 1986)

Experimental Indications - Clinical Trial Phases 1-4 (18)


 

Bacterial Infections (Phase 3)

COVID-19 (Phase 2)

Crohn Disease (Phase 4)

Cryptosporidiosis (Phase 2)

Extensively Drug-Resistant Tuberculosis (Phase 3)

Gram-Positive Bacterial Infections (Phase 3)

HIV (Phase 2)

HIV Infections (Phase 4)

Leprosy (Phase 4)

Leprosy, Lepromatous (Phase 4)

Lung Diseases (Phase 2/Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Mycobacterium avium Complex (Phase 2)

Mycobacterium avium-intracellulare Infection (Phase 3)

Mycobacterium Infections (Phase 2)

Tuberculosis (Phase 4)

Tuberculosis, Multidrug-Resistant (Phase 4)

Tuberculosis, Pulmonary (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 40
  • # of Trial Organizations: 94

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue